welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson drug startup launches gastric-cancer trial
Tucson-based drug startup Cancer Prevention Pharmaceuticals Inc. has announced the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to test the company’s flagship drug candidate for preventing gastric cancer.
The drug, CPP-1X, will be studied in patients with precancerous gastric lesions who are at high risk for gastric cancer, the company said Monday.
The trial is funded by the National Cancer Institute and run in collaboration with gastroenterologists Dr. Keith T. Wilson and Dr. Douglas R. Morgan of the Vanderbilt University School of Medicine and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
Endoscopic Submucosal Dissection to Treat Ileal High-Grade Dysplasia After Ileoanal Anastomosis for Familial Adenoma...Restorative proctocolectomy has become t...
-
8 Myths About Ostomies DebunkedMore than 750,000 Americans live with an...
-
Does a Selective Cyclooxygenase-2 Inhibitor (Tiracoxib) Induce Clinically Sufficient Suppression of Adenomas in Pati...BACKGROUND : There have been few placebo...
-
Shrinking the SilenceI’m a 28 year old, living with two ver...
-
Bonnies Diary May 08https://jtvcancersupport.com/embed/47453...
-
Intestinal Polyposis Syndromes Clinical Presentationhttp://img.medscapestatic.com/pi/meds/ck...
-
BCIR – Olympia Medical Center Los Angeleshttps://www.youtube.com/channel/UCEdZLy_...